Triiodothyronine as an adjunct in treatment of acute schizophrenia

Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine0 个研究点目标入组 60 人开始时间: 2007年3月16日最近更新: 2012年10月29日

适应症

试验速览

暂无简介。

•1.Age =18 years of old and < 50 years of old.
•2.Signed informed consent.
•3.DSM-IV diagnosis of schizophrenia 295.1 – 295.9, at least half a year.
•4.An acute psychotic episode at screening and at baseline (PANSS score 70-120, inclusive).
•5.Good physical health based on a physical examination, ECG results and laboratory tests results at screening.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Current DSM-IV axis I diagnosis other than schizophrenia.
•2.DSM-IV diagnosis of substance dependence within six month prior to screening.
•3.Any medical condition that potentially can alter absorption, metabolism or excretion of the medication (Crohn's disease, liver disease, renal disease).
•4.Injection of depot antipsychotics within 120 days before screening.
•5.History or presence of any significant or unstable cardiovascular, respiratory, neurological, seizures, cerebrovascular, renal, hepatic, endocrine or immunologic disease, unstable systemic diseases.
•6.Thyroid disorder or use of a thyroid medication.
•7.Significant risk of suicidal or violent behavior.
•8.Known allergic reactions to risperidone or T3, history of neuroleptic malignant syndrome and tardive dyskinesia.
•9.Use of MAO inhibitors within four weeks before screening
•10.ECT within three month before screening.
•11.Pregnancy or breastfeeding.

发起方

Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine